Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes

Cholody, 1990, 5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents Synthesis and biological activity, J Med Chem, 33, 49, 10.1021/jm00163a009 Cholody, 1996, Structure-activity relationship for antineoplastic imidazoacridinones: synthesis and antileukemic activity in vivo, J Med Chem, 39, 1028, 10.1021/jm950564r Skladanowski, 1996, Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors, Mol Pharmacol, 49, 772 Skwarska, 2015, Targeting of FLT3-ITD kinase contributes to high selectivity of imidazoacridinone C-1311 against FLT3-activated leukemia cells, Biochem Pharmacol, 95, 238, 10.1016/j.bcp.2015.04.006 Burger, 1996, Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer, Br J Cancer, 74, 1369, 10.1038/bjc.1996.551 Isambert, 2010, Evaluation of the safety of C-1311 administered in a phase I dose-escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumors, Eur J Cancer, 46, 729, 10.1016/j.ejca.2009.12.005 Capizzi, 2008, Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer, J Clin Oncol, 26, 1055, 10.1200/jco.2008.26.15_suppl.1055 Smith, 2011, Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents, Neoplasia, 13, 72, 10.1593/neo.101214 Berger, 1996, Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents, Cancer Res, 56, 2094 Mazerska, 2001, Enzymatic activation of a new antitumour drug, 5-diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311, observed after its intercalation into DNA, Biochem Pharmacol, 61, 685, 10.1016/S0006-2952(01)00527-5 Dziegielewski, 2002, Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity, Biochem Pharmacol, 63, 1653, 10.1016/S0006-2952(02)00916-4 Wiśniewska, 2007, Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver, Acta Biochim Pol, 54, 831, 10.18388/abp.2007_3179 Potega, 2011, The imidazoacridinone antitumor drug, C-1311, is metabolized by FMOs but not cytochrome P450s, DMD, 39, 1423, 10.1124/dmd.111.038984 Fedejko-Kap, 2012, Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10, DMD, 40, 1736, 10.1124/dmd.112.045401 Hutzler, 2006, Inhibition of cytochrome P450 by pyrimidineimidazole: evidence for complex heme interactions, Chem Res Toxicol, 19, 1650, 10.1021/tx060198m Murray, 2003, Mechanism-based inhibition of CYP activities in rat liver by fluoxetine and structurally similar alkylamines, Xenobiotica, 10, 973, 10.1080/00498250310001602748 Kalgutkar, 2007, Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions, Curr Drug Metab, 8, 407, 10.2174/138920007780866807 Ortiz de Montellano, 1991, Mechanism-based inactivation of cytochrome P450: isolation and characterization N-alkyl heme adducts, Methods Enzymol, 206, 533, 10.1016/0076-6879(91)06123-K Yamazaki, 1996, 7-Ethoxycoumarin O-deethylation catalysed by cytochromes P450 1A2 and 2E1 in human liver microsomes, Biochem Pharmacol, 51, 313, 10.1016/0006-2952(95)02178-7 Yuan, 2002, Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions, DMD, 30, 1311, 10.1124/dmd.30.12.1311 Silverman, 1996, 291 Trunzer, 2009, Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation, J Med Chem, 52, 329, 10.1021/jm8008663 Mazerska, 2003, Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311, Biochem Pharmacol, 66, 1727, 10.1016/S0006-2952(03)00477-5 Guengerich, 1995, Human cytochrome P450 enzymes, 473 Richter, 2005, Inhibition of human CYP2B6 by N,N′,N″-triethylenethiophosphoramide is irreversible and mechanism-based, Biochem Pharmacol, 69, 517, 10.1016/j.bcp.2004.10.008 Liu, 2015, Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism, Biochem Pharmacol, 97, 111, 10.1016/j.bcp.2015.07.010 Foo, 2015, Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A, Biochem Pharmacol, 97, 320, 10.1016/j.bcp.2015.07.036 De Groot, 2002, Pharmacophore modeling of cytochromes P450, Adv Drug Deliv Rev, 54, 367, 10.1016/S0169-409X(02)00009-1 Ohyama, 2000, Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions, Br J Clin Pharmacol, 49, 244, 10.1046/j.1365-2125.2000.00134.x Polasek, 2008, Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants, Br J Clin Pharmacol, 65, 87, 10.1111/j.1365-2125.2007.02964.x Wang, 2004, Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites, DMD, 32, 259, 10.1124/dmd.32.2.259 Zhao, 2002, Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites, Xenobiotica, 32, 863, 10.1080/00498250210158230 Barbara, 2012, High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling, DMD, 40, 1966, 10.1124/dmd.112.047027 Fontana, 2005, Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity, Curr Drug Metab, 6, 413, 10.2174/138920005774330639 Locuson, 2007, Visible spectra of type II cytochrome P450-drug complexes: evidence that incomplete heme coordination is common, DMD, 35, 614, 10.1124/dmd.106.012609